Table Of Content

Journal of Internal Medicine 2002; 251: 536-539 Author index Abboud, L., Hir, J., Eisen, I. & Markiewicz, W. Exercise-induced Ciceri, L. see Tedeschi, A. symptomatic ischaemia predicts a poor long-term prognosis Cohen Tervaert, J.W. see van Haelst, P.L. after acute myocardial infarction, 53 Cohen, J. see Schattner, A. Adami, H.-O. see Kuper, H. Corradi, D. see Vaglio, A. Adami, H.-O. see Tamimi, R.M. Airaghi, L. see Tedeschi, A. D'Errico, N. see Veglio, M. Allegri, L. see Vaglio, A Dalgard, O., Bjoro, K., Hellum, K., Myrvang, B., Bjoro, T., Haug, E. Almroth, G., Ekermo, B., Mansson, A.-S., Svensson, G. & Widell, & Bell, H. Thyroid dysfunction during treatment of chronic A. Detection and prevention of hepatitis C in dialysis patients hepatitis C with interferon alpha: no association with either and renal transplant recipients. A long-term follow up interferon dosage or efficacy of therapy, 400 (1989-January 1997), 119 Delaval, D. see Després, J.-P. Alper, E. see Usta, M. Després, J.-P., Lemieux, I., Salomon, H. & Delaval, D. Effects of Anan, I. see Nyhlin, N. micronized fenofibrate versus atorvastatin in the treatment of Andersson, F.L. see Bjérholt, I. dyslipidaemic patients with low plasma HDL-cholesterol Andersson, G. see Karvestedt, L levels: a 12-week randomized trial, 490 Ando, Y. see Nyhlin, N. Dilek, K. see Usta, M. Andréasson, B. see Johansson, P. Diz-Lois, F. see de la Iglesia, F. Andrés, E., Noel, E. & Maloisel, F. Nonchemotherapy drug- Djurovic, S. see Os, I. induced agranulocytosis: interest of haematopoietic growth van Doormaal, J.J. see van Haelst, P.L. factors, 533 Asplund, K. Antioxidant vitamins in the prevention of cardio- Efendic, S. see Karvestedt, L. vascular disease: a systematic review, 372 Eisen, I. see Abboud, L. Asplund, K. see Lundberg, V. Ek, A.-C. see Hollman, G. Asselbergs, F.W. see van Haelst, P.L. Ekermo, B. see Almroth, G. Aunola, S. see Marniemi, J. Eklund, A. see Planck, A. El Salhy, M. see Nyhlin, N. van Baal, W.M. see Post, M.S Elving, L.D. see Netea, R.T. Baldini, M., Gallazzi, M., Orsatti, A., Fossati, $., Leonardi, P. & Emeis, J.J. see Post, M.S. Cantalamessa, L. Treatment of benign modular goiter with Eriksson, M. see Hollman, G. mildly supressive doses of L-thyroxine. Effects on bone Erkelens, D.W. see van Venrooij, F.V. mineral density and on nodule size, 407 Ersoy, A. see Usta, M. Banga, J.D. see van Venrooij, F.V. Bargero, G. see Veglio, M. Felmeden, D.C. see Lee, K.W. Basu, S. see Vessby, J. Ferrozzi, F. see Vaglio, A. de Beer, F., Smelt, A.H.M., van Vark, L.C., Hoogerbrugge, N.., Filiz, G. see Usta, M. Havekes, L.M. & Gevers Leuven, J.A. The effect of tibolone on Fletcher, L.M. & Halliday, J.W. Haemochromatosis: understanding the lipoprotein profile of postmenopausal women with type the mechanism of disease and implications for diagnosis and III hyperlipoproteinemia, 148 patient management following the recent cloning of novel Bell, H. see Dalgard, O. genes involved in iron metabolism, 181 3engtsson, C. see Lindqvist, P. Forsblad, J. see Gottsater, A. Berg, K. see Os, I. Fossati, S. see Baldini, M. Berglund, G. see Norinder, A Fotherby, M.D. & Panayiotou, B.N. Twenty-four hour blood Berne, C. see Vessby, J pressure following stroke, 179 Bhalla, A., Wolfe, C.D.A. & Rudd, A.G. Reply to Fotherby & Frykman, V. Reply to Jolobe, 365 Panayiotou, 179 Fujimura, Y. see Orimo, S. Bjorholt, [., Andersson, F.L., Kahan, T. & Ostergren, J. The cost- effectiveness of ramipril in the treatment of patients at high Gallazzi, M. see Baldini, M. risk of cardiovascular events: a Swedish sub-study to the Gans, R.O.B. see van Haelst, P.L. HOPE study, 508 Gevers Leuven, J.A. see de Beer, F. Bjorkelund, C. see Lindqvist, P. Giannini, S. see Tedeschi, A. Bjorntorp, P. see Rosmond, R. Gilad, A. see Schattner, A. Bjoro, K. see Dalgard, O. Giner, V., Munoz, R. & Redon, J. Risperidone and severe Bjoro, T. see Dalgard, O. cerivastatin-induced rhabdomyolysis, 177 Boffetta, P. see Kuper, H. Gisslén, K., Wieslander, J., Westberg, G. & Herlitz, H. Relationship Borra, M. see Veglio, M. between anti-neutrophil cytoplasmic antibody determined Borvik, T. see Halvorsen, D.S. with conventional binding and the capture assay, and long- Bostrém, S. see Lundberg, V. term clinical course in vasculitis, 129 Bouchard, C. see Rosmond, R. Gottsiter, A., Forsblad, J., Matzsch, T., Persson, K., Ljungcrantz, Bouchard, C. see Ukkola, O. I., Ohlsson, K. & Lindgarde, F. Interleukin-1 receptor Broman, J.-E. see Mallon, L. antagonist is detectable in human carotid artery plaques and Bruno, G. see Veglio, M. is related to triglyceride levels and Chlamydia pneumoniae IgA Buzio, C. see Vaglio, A. antibodies, 61 Grill, V. see Karvestedt, L. Cantalamessa, L. see Baldini, M. Grobbee, D.E. see van Venrooij, F.\ Cavallo-Perin, P. see Veglio, M. Grunewald, J. see Planck, A. 536 © 2002 Blackwell Science Ltd Journal of Internal Medicine 2002; 251: 536-539 Author index Abboud, L., Hir, J., Eisen, I. & Markiewicz, W. Exercise-induced Ciceri, L. see Tedeschi, A. symptomatic ischaemia predicts a poor long-term prognosis Cohen Tervaert, J.W. see van Haelst, P.L. after acute myocardial infarction, 53 Cohen, J. see Schattner, A. Adami, H.-O. see Kuper, H. Corradi, D. see Vaglio, A. Adami, H.-O. see Tamimi, R.M. Airaghi, L. see Tedeschi, A. D'Errico, N. see Veglio, M. Allegri, L. see Vaglio, A Dalgard, O., Bjoro, K., Hellum, K., Myrvang, B., Bjoro, T., Haug, E. Almroth, G., Ekermo, B., Mansson, A.-S., Svensson, G. & Widell, & Bell, H. Thyroid dysfunction during treatment of chronic A. Detection and prevention of hepatitis C in dialysis patients hepatitis C with interferon alpha: no association with either and renal transplant recipients. A long-term follow up interferon dosage or efficacy of therapy, 400 (1989-January 1997), 119 Delaval, D. see Després, J.-P. Alper, E. see Usta, M. Després, J.-P., Lemieux, I., Salomon, H. & Delaval, D. Effects of Anan, I. see Nyhlin, N. micronized fenofibrate versus atorvastatin in the treatment of Andersson, F.L. see Bjérholt, I. dyslipidaemic patients with low plasma HDL-cholesterol Andersson, G. see Karvestedt, L levels: a 12-week randomized trial, 490 Ando, Y. see Nyhlin, N. Dilek, K. see Usta, M. Andréasson, B. see Johansson, P. Diz-Lois, F. see de la Iglesia, F. Andrés, E., Noel, E. & Maloisel, F. Nonchemotherapy drug- Djurovic, S. see Os, I. induced agranulocytosis: interest of haematopoietic growth van Doormaal, J.J. see van Haelst, P.L. factors, 533 Asplund, K. Antioxidant vitamins in the prevention of cardio- Efendic, S. see Karvestedt, L. vascular disease: a systematic review, 372 Eisen, I. see Abboud, L. Asplund, K. see Lundberg, V. Ek, A.-C. see Hollman, G. Asselbergs, F.W. see van Haelst, P.L. Ekermo, B. see Almroth, G. Aunola, S. see Marniemi, J. Eklund, A. see Planck, A. El Salhy, M. see Nyhlin, N. van Baal, W.M. see Post, M.S Elving, L.D. see Netea, R.T. Baldini, M., Gallazzi, M., Orsatti, A., Fossati, $., Leonardi, P. & Emeis, J.J. see Post, M.S. Cantalamessa, L. Treatment of benign modular goiter with Eriksson, M. see Hollman, G. mildly supressive doses of L-thyroxine. Effects on bone Erkelens, D.W. see van Venrooij, F.V. mineral density and on nodule size, 407 Ersoy, A. see Usta, M. Banga, J.D. see van Venrooij, F.V. Bargero, G. see Veglio, M. Felmeden, D.C. see Lee, K.W. Basu, S. see Vessby, J. Ferrozzi, F. see Vaglio, A. de Beer, F., Smelt, A.H.M., van Vark, L.C., Hoogerbrugge, N.., Filiz, G. see Usta, M. Havekes, L.M. & Gevers Leuven, J.A. The effect of tibolone on Fletcher, L.M. & Halliday, J.W. Haemochromatosis: understanding the lipoprotein profile of postmenopausal women with type the mechanism of disease and implications for diagnosis and III hyperlipoproteinemia, 148 patient management following the recent cloning of novel Bell, H. see Dalgard, O. genes involved in iron metabolism, 181 3engtsson, C. see Lindqvist, P. Forsblad, J. see Gottsater, A. Berg, K. see Os, I. Fossati, S. see Baldini, M. Berglund, G. see Norinder, A Fotherby, M.D. & Panayiotou, B.N. Twenty-four hour blood Berne, C. see Vessby, J pressure following stroke, 179 Bhalla, A., Wolfe, C.D.A. & Rudd, A.G. Reply to Fotherby & Frykman, V. Reply to Jolobe, 365 Panayiotou, 179 Fujimura, Y. see Orimo, S. Bjorholt, [., Andersson, F.L., Kahan, T. & Ostergren, J. The cost- effectiveness of ramipril in the treatment of patients at high Gallazzi, M. see Baldini, M. risk of cardiovascular events: a Swedish sub-study to the Gans, R.O.B. see van Haelst, P.L. HOPE study, 508 Gevers Leuven, J.A. see de Beer, F. Bjorkelund, C. see Lindqvist, P. Giannini, S. see Tedeschi, A. Bjorntorp, P. see Rosmond, R. Gilad, A. see Schattner, A. Bjoro, K. see Dalgard, O. Giner, V., Munoz, R. & Redon, J. Risperidone and severe Bjoro, T. see Dalgard, O. cerivastatin-induced rhabdomyolysis, 177 Boffetta, P. see Kuper, H. Gisslén, K., Wieslander, J., Westberg, G. & Herlitz, H. Relationship Borra, M. see Veglio, M. between anti-neutrophil cytoplasmic antibody determined Borvik, T. see Halvorsen, D.S. with conventional binding and the capture assay, and long- Bostrém, S. see Lundberg, V. term clinical course in vasculitis, 129 Bouchard, C. see Rosmond, R. Gottsiter, A., Forsblad, J., Matzsch, T., Persson, K., Ljungcrantz, Bouchard, C. see Ukkola, O. I., Ohlsson, K. & Lindgarde, F. Interleukin-1 receptor Broman, J.-E. see Mallon, L. antagonist is detectable in human carotid artery plaques and Bruno, G. see Veglio, M. is related to triglyceride levels and Chlamydia pneumoniae IgA Buzio, C. see Vaglio, A. antibodies, 61 Grill, V. see Karvestedt, L. Cantalamessa, L. see Baldini, M. Grobbee, D.E. see van Venrooij, F.\ Cavallo-Perin, P. see Veglio, M. Grunewald, J. see Planck, A. 536 © 2002 Blackwell Science Ltd AUTHOR INDEX 537 Gullberg, M. see Hollman, G. as assessed in the health and medical care in the Vastra Giilliilti, M. see Usta, M. Gotaland region, Sweden, 348 Gutteberg, T.J. see Halvorsen, D.S. Jolobe, O.M.P. Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics, 363 van Haelst, P.L., Asselbergs, F.W., van Doormaal, J.J., Veeger, Jolobe, O.M.P. The yield of a diagnostic hospital dyspnoea clinic N.J.G.M., May, J.F., Holvoet, P., Gans, R.O.B. & Cohen for the primary care section, 366 Tervaert, J.W. Antineutrophil cytoplasmic antibodies in patients with premature atherosclerosis: prevalence and Kaessmann, H & Paabo, S. The genetical history of humans and association with risk factors, 29 the great apes, 1 Halliday, J.W. see Fletcher, L.M. Kahan, T. see Bjdrholt, I. Halvorsen, D.S., Borvik, T., Njolstad, I., Gutteberg, T.J., Vorland, Kampmann, K. see Madsen, S.M. L.H. & Hansen, J.-B. Chlamydia pneumoniae IgA- and IgG Karlson, B.W. see Herlitz, J. antibodies in young survivors of myocardial infarction. A Karlsson, T. see Lundstam, U. comparison of antibody detection by a microimmunoflour- Karvestedt, L., Andersson, G., Efendic, S. & Grill, V. A rapid escence test and an enzyme immunoassay, 142 increase in $-cell function by multiple insulin injections in Hansen, J.-B. see Halvorsen, D.S. type 2 diabetic patients is not further enhanced by Hartiala, J. see Saaresranta, T. prolonging treatment, 307 Hartikainen, J. see Nousiainen, T. Karvonen, J., Kauma, H., Kervinen, K., Rantala, M., [kaheimo, Haug, E. see Dalgard, O. M., Paivansalo, M., Savolainen, M.J. & Havekes, L.M. see de Beer, F. Kesaniemi, Y.A. Endothelial nitric oxide synthase gene Hedbick, G. & Odén, A.S. Cardiovascular disease, hypertension Glu298Asp polymorphism and blood pressure, and renal function in primary hyperparathyroidism, 476 left ventricular mass and carotid artery atherosclerosis Hedblad, B. see Norinder, A. in a population-based cohort, 102 Heise, T. & Sawicki, P.T. Does insulin preserve B-cell function in Katzman, P. see Léndahl, M. type 2 diabetes? 283 Kauma, H. see Karvonen, J. Hellum, K. see Dalgard, O. Keber, I. see Sebestjen, M. Hendriks, D.F. see Post, M.S. Kenemans, P. see Post, M.S. Herlitz, H. see Gisslén, K. Kervinen, K. see Karvonen, J. Herlitz, J. see Lundstam, U. Kesaniemi, Y.A. see Karvonen, J. Herlitz, J., Karlson, B.W., Sjdlin, M. & Lindqvist, J. Ten-year Koskenvuo, M. see Marniemi, J. mortality for patients discharged after hospitalization for Kronholm, E. see Marniemi, J. chest pain or other symptoms raising suspicion of acute Kuper, H., Adami, H.-O. & Boffetta, P. Tobacco use, cancer myocardial infarction in relation to hospital discharge causation and public health impact, 455 diagnosis, 526 Kutti, J. see Johansson, P. Hetta, J. see Mallon, L. Hiatt, W.R. Preventing atherothrombotic events in peripheral Lagiou, P. see Tamimi, R.M. arterial disease: the use of antiplatelet therapy, 193 Lahoz, C. see Pena, R. Hilsted, K.L. see Madsen, S.M. Lee, K.W., Felmeden, D.C. & Lip, G.Y.H. Statins and the Hir, J. see Abboud, L. assessment of endothelial function, 452 Hoffmann, J.C., Pistorius, G., Miiller, P. & Zeitz, M. Unusual case of Lemieux, I. see Després, J.-P. a large mideosophageal diverticulum mimicking unstable Leonardi, P. see Baldini, M. angina pectoris, 355 Leurs, J.R. see Post, M.S. Hollman, G., Gullberg, M., Ek, A.-C., Eriksson, M. & Olsson, A.G. Lindén, T. see Lundstam, U. Quality of life in patients with familial hypercholesterolaemia, Lindgarde, F. see Gottsater, A. 33] Lindmark, H. see Svensson, L. Holm, S. see Madsen, S.M. Lindqvist, J]. see Herlitz, J. Holvoet, P. see van Haelst, P.L. Lindqvist, P., Bengtsson, C., Lissner, L. & Holzmann, M., Olsson, A., Johansson, J. & Jensen-Urstad, M. Left Bjorkelund, C. Cholesterol and triglyceride concentration as ventricular diastolic function is related to glucose in a middle- risk factors for myocardial infarction and death in women, aged population, 415 with special reference to influence of age, 484 Hoogerbrugge, N. see de Beer, F. Lip, G.Y.H. see Lee, K.W. Hurt-Camejo, E. see Wiklund, O. Lissner, L. see Lindqvist, P. Ljungcrantz, I. see Gottsater, A. de la Iglesia, F., Valino, P., Pita, $., Ramos, V., Pellicer, C., Nicolas, Ljungdahl, L. see Londahl, M. R. & Diz-Lois, F. Factors predicting a hospital stay of over 3 Léndahl, M., Katzman, P., Nilsson, A., Ljungdahl, L. & Prutz, K.-G. days in patients with acute exacerbation of chronic Cardiovascular prevention before admission reduces mortal- obstructive pulmonary disease, 500 ity following acute myocardial infarction in patients with Ikaheimo, M. see Karvonen, J. diabetes, 325 Irjala, K. see Saaresranta, T. Lopez-Pastor, A. see Pena, R. Ishizashi, H. see Orimo, S. Lundberg, V., Wikstrém, B., Bostrém, S. & Asplund, K. Exploring Ito, Y. see Yamakawa, T. sex differences in case fatality in acute myocardial infarction or coronary death events in the northern Sweden MONICA Jantunen, E. see Nousiainen, T. Project, 235 Jensen-Urstad, M. see Holzmann, M. Lundstam, U., Herlitz, J., Karlsson, T., Lindén, T. & Wiklund, Jiménez, J. see Pena, R. O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) Johansson, J. see Holamann, M. isoforms as prognostic markers in patients with coronary Johansson, P., Andréasson, B., Safai-Kutti, S., Rhedin, C., Vilén, heart disease, 111 L., Vaart, J. & Kutti, J. On the diagnosis of polycythaemia vera Lutterman, J.A. see Netea, R.T. © 2002 Blackwell Science Ltd Journal of Internal Medicine 251: 536-539 538 AUTHOR INDEX Macchia, G. see Veglio, M. disease. A possible mechanism for the putative cardiopro- Madsen, S.M., Mirza, M.R., Holm, S., Hilsted, K.L., Kampmann, K. tective role of TGF-B,? 223 & Riis, P. Attitudes towards clinical research amongst Oscarsson, J. see Wiklund, O. participants and nonparticipants, 156 Ostergren, J. see Bjérholt, I. Mallon, L., Broman, J.-E. & Hetta, J. Sleep complaints predict Ozawa, E. see Orimo, S. coronary artery disease mortality in males: a 12-year follow- Ozbek, S. see Usta, M. up study of a middle-aged Swedish population, 207 Ozdemir, B. see Usta, M. Maloisel, F. see Andrés, E. Manenti, L. see Vaglio, A. Paabo, S. see Kaessmann, H. Mansson, A.-S. see Almroth, G. Pagano, G.F. see Veglio, M. Markiewicz, W. see Abboud, L. Padivansalo, M. see Karvonen, J. Marniemi, J., Kronholm, E., Aunola, S., Toikka, T., Mattlar, C.-E., Palace, M.R. see Vlassara, H. Koskenvuo, M. & Rénnemaa, T. Visceral fat and psychosocial Palmblad, J. Reply to Andrés et al., 535 stress in identical twins discordant for obesity, 35 Panayiotou, B.N. see Fotherby, M.D. Massari, F.M. see Tedeschi, A. Pedersen, J.I. see Yli-Jama, P. Matsumoto, M. see Orimo, S. Pellicer, C. see de la Iglesia, F. Mattlar, C.-E. see Marniemi, J. Pena, R., Lahoz, C., Mostaza, J.M., Jiménez, J., Subirats, E., Pinto, Mattsson Hultén, L. see Svensson, L. X., Taboada, M., Lopez-Pastor, A. & The Rap Study Group, A. Mattsson-Hultén, L. see Wiklund, O. Effect of apoE genotype on the hypolipidaemic response to Matzsch, T. see Gottsater, A. pravastatin in an outpatient setting, 518 May, J.F. see van Haelst, P.L. Persson, K. see Gottsater, A. Meyer, H.E. see Yli-Jama, P. Persson, U. see Norinder, A. Mirza, M.R. see Madsen, S.M. Pinto, X. see Pena, R. Mohsen, R. see Vessby, J. Pistorius, G. see Hoffmann, J.C. van der Mooren, M.J. see Post, M.S. Pita, S. see de la Iglesia, FP. Mostaza, J.M. see Pena, R. Planck, A., Eklund, A., Yamaguchi, E. & Grunewald, Miiller, P. see Hoffmann, J.C. J. Angiotensin-converting enzyme gene polymorphism in Munoz, R. see Giner, V. relation to HLA-DR in sarcoidosis, 217 Myrvang, B. see Dalgard, O Polo, O. see Saaresranta, T. Post, M.S., Hendriks, D.F., van der Mooren, M.J., van Baal, W.M., Netea, R.T., Elving, L.D., Lutterman, J.A. & Thien, Th. Body Leurs, J.R., Emeis, J.J., Kenemans, P. & Stehouwer, C.D.A. position and blood pressure measurement in patients with Oral oestradiol/trimegestone replacement reduces procar- diabetes mellitus, 393 boxypeptidase U (TAFI): a randomized, placebo-controlled, Nicolas, R. see de la Iglesia, | 12-week study in early postmenopausal women, 245 Nilsson, A. see Londahl, M. Prutz, K.-G. see Londahl, M. Nilsson, J.-A. see Norinder, A. Puustinen, J. see Nousiainen, T. Nilsson, P. see Norinder, A. Njolstad, I. see Halvorsen, D.S. Ramos, V. see de la Iglesia, F. Noel, E. see Andrés, E. Rantala, A. see Nousiainen, T. Norén, K. see Svensson, L. Rantala, M. see Karvonen, J. Norinder, A., Persson, U., Nilsson, P., Nilsson, J.-A., Hedblad, B. & Redon, J. see Giner, V. Berglund, G. Costs for screening, intervention, and hospital Remes, J. see Nousiainen, T. treatment generated by the Malm6 Preventive Project: a Rhedin, C. see Johansson, P. large-scale community screening programme, 44 Riis, P. see Madsen, S.M. Nousiainen, T., Vanninen, E., Jantunen, E., Puustinen, J., Remes, Ringstad, J. see Yli-Jama, P. J., Rantala, A., Vuolteenaho, O. & Hartikainen, J. Natriuretic ROnnemaa, T. see Marniemi, J. peptides during the development of doxorubicin-induced left Rosengren, A., Thelle, D. & Wilhelmsen, L. Parental age and ventricular diastolic dysfunction, 228 coronary disease in the general male population, 258 Nyhlin, N., Anan, I., El Salhy, M., Ando, Y. & Suhr, O.B. Rosmond, R., Bouchard, C. & Bjérntorp, P. A C-1291G Reduction of free radical activity in amyloid deposits polymorphism in the >,-adrenergic receptor gene (ADRA2A) following liver transplantation for familial amyloidotic promoter is associated with cortisol escape from dexametha- polyneuropathy, 136 sone and elevated glucose levels, 252 Roéssner, S. see Sharma, A.M. Odén, A.S. see Hedback, G. Rudd, A.G. see Bhalla, A. Ohlsson, B. see Svensson, L. Ohlsson, K. see Gottsiter, A. Saaresranta, T., Uotila, P., Saraste, M., Irjala, K., Hartiala, J. & Olsson, A. see Holzmann, M. Polo, O. Effect of medroxyprogesterone on pulmonary arterial Olsson, A.G. see Hollman, G. pressure, exhaled nitric oxide, ECG and arterial blood gases, Olsson, R. Can doxycycline cause polyneuropathy? 361 421 Orimo, S., Ozawa, E., Yagi, H., Ishizashi, H., Matsumoto, M. & Safai-Kutti, S$. see Johansson, P. Fujimura, Y. Simple plasma exchange reduced autoantibody Salomon, H. see Després, J.-P. to von Willebrand factor-cleaving protease in a Japanese man Santaniemi, M. see Ukkola, O. with ticlopidine-associated thrombotic thrombocytopenic Saraste, M. see Saaresranta, T. purpura, 280 Savolainen, M.J. see Karvonen, J. Orsatti, A. see Baldini, M. Sawicki, P.T. see Heise, T. Os, I., Djurovic, S., Seljeflot, I. & Berg, K. Transforming growth Schattner, A., Gilad, A. & Cohen, J. Systemic granulomatosis and factor (TGF)-B; inversely related to vascular cell adhesion hypercalcaemia following intravesical bacillus Calmette- molecule-1 in postmenopausal women with coronary artery Guérin immunotherapy, 272 2002 Blackwell Science Ltd Journal of Internal Medicine 251: 536-539 AUTHOR INDEX 359 Sebestjen, M., Zegura, B. & Keber, I. Both cerivastatin and Vaart, J. see Johansson, P. fenofibrate improve arterial vasoreactivity in patients with Vaglio, A., Manenti, L., Allegri, L., Ferrozzi, F., Corradi, D. & Buzio, combined hyperlipidemia, 77 C. ANCA-positive periaortic vasculitis: does it fall within the Sebestjen, M., Zegura, B. & Keber, I. Statins and the assessment of spectrum of vasculitus? 268 endothelial function — response to Lee et al., 453 Valino, P. see de la Iglesia, FP. Sekihara, H. see Yamakawa, T. Vanninen, E. see Nousiainen, T. Seljeflot, I. see Os, I. van Vark, L.C. see de Beer, F. Shadid, S. & Ter Maaten, J.C. Sarcoidosis — a great mimicker, Veeger, N.J.G.M. see van Haelst, P.L. 174 Veglio, M., Bruno, G., Borra, M., Macchia, G., Bargero, G.., Sharma, A.M. & Réssner, S. Who cares about the obese D'Errico, N., Pagano, G.F. & Cavallo-Perin, P. Prevalence of hypertensive patient? 369 increased QT interval duration and dispersion in type 2 Shoji, A. see Yamakawa, T. diabetic patients and its relationship with coronary heart Sjélin, M. see Herlitz, J. disease: a population-based cohort, 317 Smelt, A.H.M. see de Beer, F. Venrooij, F.V., Stolk, R.P., Banga, J.D., Erkelens, D.W. & Stehouwer, C.D.A. see Post, M.S. Grobbee, D.E. Primary and secondary prevention in cardio- Stolk, R.P. see van Venrooij, F.V. vascular disease: an old-fashioned concept? 301 Subirats, E. see Pena, R. Vessby, B. see Vessby, J. Suhr, O.B. see Nyhlin, N. Vessby, J., Basu, S., Mohsen, R., Berne, C. & Vessby, B. Oxidative Svensson, G. see Almroth, G. stress and antioxidant status in type 1 diabetes mellitus, 69 Svensson, L., Norén, K., Wiklund, O., Lindmark, H., Ohlsson, B. & Vilén, L. see Johansson, P. Mattsson Hultén, L. Inhibitory effects of N-acetylcysteine or. Vlassara, H. & Palace, M.R. Diabetes and advanced glycation scavenger receptor class A expression in human macro- endproducts, 87 phages, 437 Vorland, L.H. see Halvorsen, D.S. Vuolteenaho, O. see Nousiainen, T. Taboada, M. see Pena, R. Tamimi, R.M., Lagiou, P., Adami, H.-O. & Trichopoulos, Westberg, G. see Gisslén, K. D. Prospects for chemoprevention of cancer, 286 Widell, A. see Almroth, G. Tanaka, S.-I. see Yamakawa, T. Wieslander, J. see Gisslén, K. Tedeschi, A., Airaghi, L., Giannini, S., Ciceri, L. & Massari, F.M. Wiklund, O. see Lundstam, U. High-dose intravenous immunoglobulin in the treatment of Wiklund, O. see Svensson, L. acute myocarditis. A case report and review of the literature, Wiklund, O., Mattsson-Hultén, L., Hurt-Camejo, E. & Oscarsson, J. 169 si Effects of simvastatin and atorvastatin on inflammation Ter Maaten, J.C. see Shadid, S. markers in plasma, 338 The Rap Study Group see Pena, R. Wikstrém, B. see Lundberg, V. Thelle, D. see Rosengren, A. Wilhelmsen, L. see Rosengren, A. Thien, Th. see Netea, R.T. Wolfe, C.D.A. see Bhalla, A. Toikka, T. see Marniemi, J. Tremblay, A. see Ukkola, O. Yagi, H. see Orimo, S. Trichopoulos, D. see Tamimi, R.M. Yamaguchi, E. see Planck, A. Yamakawa, T., Tanaka, S.-I., Ito, Y., Shoji, A. & Sekihara, H. Ukkola, O. & Santaniemi, M. Protein tyrosine phosphatase 1B: Recurrent pneumonia with unconsciousness, 278 a new target for the treatment of obesity and associated Yavuz, M. see Usta, M. co-morbidities, 467 Yli-Jaina, P., Meyer, H.E., Ringstad, J. & Pedersen, J.I. Serum free Ukkola, O., Tremblay, A. & Bouchard, C. Lipoprotein lipase fatty acid pattern and risk of myocardial infarction: a case- polymorphisms and responses to long-term overteeding, 429 control study, 19 Uotila, P. see Saaresranta, T. Yurtkuran, M. see Usta, M. Usta, M., Dilek, K., Ersoy, A., Alper, E., Ozbek, S., Ozdemir, B., Filiz, G., Yavuz, M., Gilliilii, M. & Yurtkuran, M. A family with Zegura, B. see Sebestjen, M. IgA nephropathy and hereditary lymphoedema Zegura, B. see Sebestjen, M. praecox, 447 Zeitz, M. see Hoffmann, J.C. © 2002 Blackwell Science Ltd Journal of Internal Medicine 251: 536-539 Journal of Internal Medicine 2002; 251: 540- Keyword index absolute risk, 301 diastolic, 228 molecular evolution, 1 acute myocardial infarction, 235 diet-derived agents, 286 mortality, 53, 111, 207, 325, 484 adaptation, 331 differential diagnosis, 355 myocardial infarction, 53, 19, 325, adenosine diphosphate (ADP) receptor doxorubicin, 228 526 antagonists, 193 dydrogesterone, 245 myocardial ischaemia, 526 adrenergic receptor, 252 dyslipidaemia, 490 myocarditis, 169 advanced glycation endproducts (AGE), 87 echocardiography, 228 natriuretic peptides, 228 age, 484 EIA test, 142 neuropathic oxidative stress, 136 amyloidosis, 136 epidemiology, 207 nitric oxide, 102 angina, 53 erythropoietin, 348 nonesterified fatty acids, 19 angina pectoris, 355 E-selectin, 223 noradrenaline, 35 angiotensin-converting enzyme gene exercise, 53 polymorphism, 217 obesity, 35, 467 anti-inflammatories, 286 familial hypercholesterolaemia, 331 oestradiol, 245 anti-neutrophil cytoplasmic antibody, fenofibrate, 77, 490 omega-3 fatty acids, 19 29, 129, 268 outpatient, 518 antioestrogens, 286 genes, 252 antioxidants, 69, 286 genetics, 102 patient recruitment, 156 antiplatelet therapy, 193 glomerulonephritis, 268 peripheral artery disease, 193 anxiety, 331 great apes, 1 personal health, 331 apolipoprotein E, 518 phospholipase A2, 338 arterial vasoreactivity, 77 HDL-cholesterol, 490 polycythaemia vera, 348 asprin, 193 hepatitis C virus, 119 polymerase chain reaction (PCR), 119 atherosclerosis, 102, 193 hereditary, 136 polymorphism, 252 atorvastatin, 338, 490 heredity, 258 polyunsaturated fatty acids, 19 autoimmunity, 29 HFE gene, 181 population study, 258 HLA class II, 217 postmenopausal women, 223 blood pressure, 252 HOPE, 508 pravastatin, 518 hormone replacement therapy, 148, premature atherosclerosis, 29 cancer, 286, 455 245 prevention, 45, 325 carcinogenesis, 455 humans, | primary hyperparathyroidism, 476 cardiovascular, 44 hypercalcaemia, 476 primary prevention, 301 cardiovascular disease(s), 111, 193, 476, hyperglycaemia, 307 procarboxypeptidase U, 245 508 hyperparathyroidism, 476 prognosis, 217, 526 carotid artery stenosis, 61 hypertension, 102, 476 prospective studies, 508 case fatality, 235 protein tyrosine phosphatase 1B, 467 cerivastatin, 77 ICAM-1, 223, 338 proteinase 3, 129 chemoprevention, 286 identical twins, 35 psychosocial stress, 35 Chlamydia pneumoniae, 61 IL-6, 338 Chlamydia pneumoniae antibodies, 142 inflammation, 29 OT interval, 317 cholesterol, 518 insomnia, 207 quality of life, 331 chronic obstructive pulmonary disease, insulin resistance, 467 500 insulin secretion, 307 ramipril, 508 combined hyperlipidaemia, 77 insulin sensitivity, 307 randomized controlled trials, 156 coronary artery disease, 207, 325 insulin treatment, 307 recombinant immunoblot assay, 119 coronary death, 235 interleukin-1 receptor antagonist, 61 red cell mass, 348 coronary disease, 19, 53, 207, 223, 235, interleukin-1B, 61 renal disease, 129 258, 317, 325, 490 intestinal iron absorption, 181 renal function, 476 coronary heart disease, 223, 317, 490 intravenous immunoglobulin, 169 research ethics, 156 cortisol, 35, 252 iron overload, 181 resection, 355 cost analysis, 45 isoforms, 111 retroperitoneal fibrosis, 268 cost benefit analysis, 508 isoprostanes, 69 risk factors, 325 C-peptide glucagon test, 307 CRP, 338 length of stay, 500 sarcoidosis, 217 cyclophosphamide, 268 lipid peroxidation, 69 screening programme, 45 lipoprotein(a), 111 secondary prevention, 301 DAN sequence variation, 1] lipoproteins, 111, 148 seroprevalence, 142 depression, 207 liver, 136, 181 serum amyloid, 338 diabetes, 87 logistic regression, 500 serum free fatty acids, 19 diabetes mellitus, 69, 325 longevity, 258 serum lipids, 484 diabetes — type 2, 307 Sex, 235 diabetic neuropathy, 317 medical ethics, 156 Short Stay Medical Unit, 500 diagnosis, 235 micoscopic polyarteritis, 129 simvastatin, 338 diagnostic criteria, 348 midoesophageal diverticulum, 3 5 5 smoking, 455, 484 dialysis, 119 MIF test, 142 spleen size, 348 540 © 2002 Blackwell Science Ltd KEYWORD INDEX 541 study prospective, 207 transmission, 119 vasa-vasorum, 268 survey, 317 transthyretin, 136 vasculitis, 268 survival, 53 treatment, 235 VCAM-1, 223 systolic, 228 trial participation, 156 visceral fat, 35 triglycerides, 61, 518 thrombin-activatable fibrinolysis inhibi- trimegestone, 245 Wegener's granulomatosis, 129 tor, 245 transplantation, 136 women, 111, 484 tibolone, 148 type 2 diabetes, 307 tobacco, 455 type III hyperlipoproteinemia, 148 transforming growth factor-B), 223 © 2002 Blackwell Science Ltd Journal of Internal Medicine 251: 540-541